TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02644278
Drug: VX-984 720 mg + PLD 40 mg/m^2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received VX-984 orally 720 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 720 mg in combination with PLD 40 mg/m\^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m\^2.
Study: NCT02025192
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m\^2 administered twice per day, orally in Days 1-14 of each 21-day cycle.
Study: NCT02458781
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given twice daily for 14 days
Study: NCT04488016
Drug: Treatment A- Part 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive 100 mg acalabrutinib capsule, fasted state;
Study: NCT04488016
Drug: Treatment B- Part 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fasted state
Study: NCT04488016
Drug: Treatment C - Part 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fed state
Study: NCT04358965
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
Study: NCT01566786
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose of trial drug 10 mcg/kg, escalating up to five dose tiers: 20 mcg/kg, 40 mcg/kg, 80 mcg/kg, 120 mcg/kg and 160 mcg/kg. Administered within the first 4 hours after the insult
Study: NCT02562443
Drug: Any approved or standard-of-care therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Physician's Choice of Treatment or alternative treatment which may include any approved or standard-of-care therapy, based on frequently used treatment for MDS (no experimental therapy) + best supportive care.
Study: NCT02562443
Drug: best supportive care (BSC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive best supportive care (BSC): azacitidine (AZA) and/or decitabine (DAC) are permitted.
Study: NCT02562443
Drug: best supportive care (BSC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive best supportive care (BSC).
Study: NCT00513188
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00513188
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00513188
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00513188
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01228331
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: together wit MTX and ASP in consolidation and together with cytarabine and 6-TG in reinduction
Study: NCT01228331
Drug: Doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: part of reinduction therapy
Study: NCT01228331
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: part of different chemotherapy blocks
Study: NCT01228331
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: part of different chemotherapy blocks
Study: NCT01660386
Drug: Blank control
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: the subjects take no medication at experimental day and start bi-phase hyperglycaemic clamp at 9am.
Study: NCT00789360
Drug: Inhaled Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Staccato Placebo, 2 inhalations, 8 hours apart
Study: NCT03139604
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets administered orally once daily (QD) plus corticosteroids.
Study: NCT00206388
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fixed dose of 25mg/m2/dose days 0-27
Study: NCT00142090
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline
Study: NCT01454180
Drug: gemcitabine, or gemcitabine and capecitabine, or gemcitabine and erlotinib, or FOLFIRINOX, or FOLFOX, or FOLFIRI.
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks.~* Gemcitabine - Capecitabine (GEM-CAP):Gemcitabine 1000 mg/m2 weekly for 3 weeks, Capecitabine 830 mg/m2 orally every 12 hours daily for 3 weeks; every 4 weeks.~* Gemcitabine-Erlotinib: Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks, Erlotinib 100 mg orally daily~* FOLFOXIRI: Oxaliplatin 85 mg/m2,irinotecan 180 mg/m2, folinic acid 400 mg/m2, 5'Fluouracilo 400 mg / m2, 5 'fluorouracil 2400 mg/m2 continuous intravenous infusion of 46 hours. Repeated every 14 days.~* FOLFOX: Oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo, 2400 mg/m2 5'Fluouracilo continuous intravenous infusion of 46 hours. Repeated every 14 days.~* FOLFIRI: Irinotecan 180 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo intravenous bolus, 5'Fluouracilo 2400 mg / m2 continuous intravenous infusion for 46 hours. Repeated every 14 days.
Study: NCT01454180
Drug: Gemcitabine, Gemcitabine-Capecitabine, Gemcitabine-Erlotinib, FOLFOXIRI, FOLFOX, FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks.~* Gemcitabine - Capecitabine (GEM-CAP):Gemcitabine 1000 mg/m2 weekly for 3 weeks, Capecitabine 830 mg/m2 orally every 12 hours daily for 3 weeks; every 4 weeks.~* Gemcitabine-Erlotinib: Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks, Erlotinib 100 mg orally daily~* FOLFOXIRI: Oxaliplatin 85 mg/m2,irinotecan 180 mg/m2, folinic acid 400 mg/m2, 5'Fluouracilo 400 mg / m2, 5 'fluorouracil 2400 mg/m2 continuous intravenous infusion of 46 hours. Repeated every 14 days.~* FOLFOX: Oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo, 2400 mg/m2 5'Fluouracilo continuous intravenous infusion of 46 hours. Repeated every 14 days.~* FOLFIRI: Irinotecan 180 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo intravenous bolus, 5'Fluouracilo 2400 mg / m2 continuous intravenous infusion for 46 hours. Repeated every 14 days.
Study: NCT02206477
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02383940
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, once daily before the first meal of the day
Study: NCT03926195
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match filgotinib tablet administered orally once daily
Study: NCT04374539
Drug: Standar medical treatmen
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kaletra: lopinavir/ritonavir: 2c/12h 7 days~* Hydroxychloroquine sulfate 400 mg/12h the first day followed by 200 mg /12h 4 days~* Azithromycin 500 mg first day, followed by 250 mg /d 4 days (oral or EV)~* Tocilizumab 400 mg (weight \<75Kgs) or 600 mg (weight ≥ 75 Kg)~* Methylprednisolone 250 mg EV three days and 30 mg/d another 3 days~* Anakinra 200mg/ 12h SBC first day, 200mg / 24h SBC two more days~* Clexane 40-60 mg/d
Study: NCT02251769
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00564746
Drug: A single 10 milligram (50 microcurie) oral dose of [14C]SB-681323
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\] SB-681323 oral solution, is available as a powder which will be made into a solution of 0.1 milligram/milliliter (0.5 microcurie) \[14C\] SB-681323 in dextrose and water for injection on the day prior to dosing.~For a 10 milligram/50 microcurie oral dose of \[14C\]SB-681323, 100 milliliters of 0.1 milligram/milliliter (0.5 microcurie/milliliter \[14C\] SB-681323 oral solution will be dosed.
Study: NCT04297631
Drug: Tobramycin Powder
Normalized name: tobramycin Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everyone gets tobramycin powder.
Study: NCT00469781
Drug: 2. Xibrom (Bromfenac)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 and 2: 1 drop(Instill one drop in the eye that was operated on twice daily)3 days prior to surgery and 4 doses during dilation immediately before the procedure. Use for 4 weeks after surgery.
Study: NCT00203905
Drug: 5-Fluorouracil, Hydroxyurea-[FHX]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea at 500 mg PO q 12 hours x 6 days; Infusion of 5-FU (600 mg/m2/day) X 5 days (120 hours)
Study: NCT01399697
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: orally, Week 1 - 16
Study: NCT01399697
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: orally, Week 17-28
Study: NCT01399697
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: methotrexate placebo orally, Week 17-28
Study: NCT02207491
Drug: AR-13324 Ophthalmic Solution 0.02%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop once daily (QD), PM, OU
Study: NCT00277589
Drug: Levothyroxin-Na
Normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 tablet 30 minutes before breakfast
Study: NCT00277589
Drug: Levothyroxine-Na + iodide
Normalized name: levothyroxine sodium / potassium iodide Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet 30 minutes before breakfast
Study: NCT00277589
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet 30 minutes before breakfast
Study: NCT02233803
Drug: NEUMOTEROL 400 (BFF 400/12 mcg) single capsule inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized 400 mcg budesonide+ 12 mcg formoterol fumarate along with micronized and crystalline lactose monohydrate (excipient), per capsule dispensed by single capsule inhaler, twice daily (administered once in the morning and once in the evening approximately 12 hours later).
Study: NCT02233803
Drug: SYMBICORT forte (BFF 320/9mcg) TURBUHALER inhaler
Normalized name: Symbicort Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unit dose containing 320 mcg budesonide and 9 mcg formoterol fumarate (as dihidrate) along with lactose monohydrate as excipient. Administered as inhalation by TURBUHALER inhaler, twice daily (once in the morning and once in the evening approximately 12 hours later)
Study: NCT02233803
Drug: NEUMOTEX 400 (Budesonide 400 mcg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 400mcg will be administered to all the subjects twice daily, during the Run-in and Washout Periods
Study: NCT01745692
Drug: Intravenous rtPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients receive IV alteplase
Study: NCT00006375
Drug: LY293111
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04224857
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or daily dosing at doses A, B, C, D, E, F
Study: NCT01661764
Drug: Eicosapentanoic acid and docosahexanoic acid
Normalized name: docosahexaenoic acid / eicosapentaenoic acid Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1395 mg EPA plus 1125 mg DHA daily for 24 weeks
Study: NCT02922673
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02268825
Drug: MK-3475
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-3475 in combination with mFOLFOX6 in a 14 day cycle~Phase 1 and safety expansion Phased Regimen mFOLFOX6 Administered Day 1 of each cycle Leucovorin 400 mg/m2 IV 5-FU 400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hrs Oxaliplatin (Eloxatin) 85 mg/m2 IV~MK-3475 IV to be administered before mFOLFOX6 starting with Cycle 3 (after 28 days of chemotherapy alone); day 1 of each cycle (q 2 weeks)~Phase 1: 2 dose levels of MK-3475 Level -1: 50mg IV q 2 weeks Level 1: 75mg IV q 2 weeks Level 2: 200mg IV q 2 weeks~Safety Expansion: MK-3475 at highest tolerated dose
Study: NCT03183505
Drug: Anyu Peibo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anyu Peibo Capsule, 0.8g twice per day, oral after breakfast and supper
Study: NCT03183505
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Capsule, twice per day, oral after breakfast and supper
Study: NCT01383655
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl
Study: NCT00539305
Drug: testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50-100mg applied topically daily for six months
Study: NCT00539305
Drug: placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: applied topically daily for six months
Study: NCT02601586
Drug: Levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa
Study: NCT01404429
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Different doses for both arms followed by similar escalation (2.5 mg every 15 d) till max of 25 mg per week or 3 months completed
Study: NCT03653208
Drug: hzVSF-v13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form: 10mg / 20mg / 50mg / 100mg / 200mg / 400mg / 800mg / 1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1 (single administration)
Study: NCT03653208
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form: 0.9% NaCl Solution Frequency: Dose at Day 1 (single administration)
Study: NCT01363908
Drug: SPD602
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02601586
Drug: Levodopa placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04016051
Drug: Clarithromycin DST (125 mg)
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin DST (125.0 mg clarithromycin / straw).
Study: NCT04016051
Drug: Clarithromycin DST (187.5 mg)
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin DST (187.5 mg clarithromycin / straw).
Study: NCT04016051
Drug: Clarithromycin DST (250 mg)
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin DST (250.0 mg clarithromycin / straw).
Study: NCT04016051
Drug: Clarithromycin Syrup (125 mg)
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin Syrup 2.5 ml (125 mg).
Study: NCT04016051
Drug: Clarithromycin Syrup (187.5 mg)
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin Syrup 3.75 ml (187.5 mg).
Study: NCT04016051
Drug: Clarithromycin Syrup (250 mg)
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin Syrup 5 ml (250 mg).
Study: NCT03752970
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravenously every 4 weeks (week 0, 4, 8). At week 12 achievement of combined perianal fistula remission was determined, patients without combined perianal fistula remission were switched to spesolimab and were treated with spesolimab 1200 milligram intravenously every 4 weeks (week 12, 16 and 20). Patients with combined perianal fistula remission remained on Placebo and were treated with placebo intravenously every 4 weeks (week 12, 16 and 20).
Study: NCT00354575
Drug: Chinese Herb: CCH1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5/3.0/4.5gm powder per day for mild/moderate/severe constipation
Study: NCT04385550
Drug: AK105 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK105 200mg intravenously (IV) on Day 1 of each 21-day cycle.
Study: NCT04343222
Drug: Bromfenac
Normalized name: Bromfenac
DrugBank: Bromfenac (DB00963)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An NSAID used to treat eye pain and swelling
Study: NCT03225846
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Sodium Chloride
Study: NCT01747551
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01883102
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream will be cleansed from sites A and B with soap and water each morning before reapplying.
Study: NCT01868425
Drug: multimodal:acetaminophen, gabapentin, ketamine, bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: acetaminophen, gabapentin, ketamine, bupivacaine and standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane
Study: NCT01868425
Drug: placebo pills and injectables
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: receives standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane plus placebos of intervention arm meds
Study: NCT00397670
Drug: Drug: BufferGel® with diaphragm
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03796377
Drug: St Johns Wort Extract
Normalized name: St Johns wort extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg rivaroxaban after supplementation with St. John's wort extract (Jarsin®) twice daily 450 mg po for 2 weeks.
Study: NCT02839889
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for two weeks, followed by two week open-label period
Study: NCT04353505
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-arterial delivery of Ketorolac in the internal maxillary artery, once
Study: NCT00542542
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50-250 mcg IV over 1-4 hours during surgery.
Study: NCT01730014
Drug: 148-0287-A-4.2mM-cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: In a dose-escalating design, healthy subjects will receive a single dose, injected subcutaneously.
Study: NCT01730014
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In a dose-escalating design, healthy subjects will receive 148-0287-A-placebo-cartridge, injected subcutaneously.
Study: NCT01730014
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In a dose-escalating design, subjects with type 1 diabetes will receive 148-0287-A-placebo-cartridge in a single dose, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.
Study: NCT01156077
Drug: TR-701 FA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral TR-701 FA 200 mg will be given as a single oral dose
Study: NCT01156077
Drug: TR-701 FA
Approvals — FDA: no, EMA: no, PMDA: no
Description: TR-701 FA 200 mg will be given as a single 60 minute IV infusion in 250 cc saline
Study: NCT02548286
Drug: CKD-330 8/5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, 1day or 22day
Study: NCT02801695
Drug: Citrulline
Normalized name: Citrulline
DrugBank: Citrulline (DB00155)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citrulline supplementation
Study: NCT02801695
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00783276
Drug: SYN115
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg single dose
Study: NCT00783276
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLACEBO
Study: NCT00547014
Drug: Placebo Comparator: Cohort 1 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: placebo for cohort 1 as single dose
Study: NCT00547014
Drug: Placebo Comparator: Cohorts 2, 3, 4 & 5 Two subjects each arm will be assigned to receive placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo for cohorts 2, 3, 4 and 5 administered as a single dose
Study: NCT00547014
Drug: 52364 100 mg
Normalized name: TUBE FEEDING GT 20FR ROSS#51364
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug 52364 100 mg capsule administered as a single dose
Study: NCT00211068
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study is an observational study. No medication will be provided or administered to the participants. Participants will receive standard-of-care treatment from their individual physicians.
Study: NCT01718808
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/m2 bid p.o. (750 mg/m2 if creatinine clearance 30-50 ml/min according to Cockroft-Gault formula, on days 1-14 every 3 weeks, restart on day 22
Study: NCT00450515
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04557267
Drug: Higher-dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage 3
Study: NCT04557267
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01805453
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide + Placebo 2/day until the halting for any reason
Study: NCT04223804
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion
Study: NCT02993406
Drug: Matching placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients take matching placebo tablet orally once daily
Study: NCT01824927
Drug: Steroids eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use steroids eye drops to decrease the pain.
Study: NCT01237236
Drug: LEE011
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02963051
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg three times a day~Source of disulfiram: Cantex Pharmaceuticals
Study: NCT00663962
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An identical placebo administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op (N=8)